Trial · NCT03037385
Adverse events2,068
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 2,068
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Pralsetinib ≤ 300 mg QD | 16 | 37 | 45 |
| other | Anaemia | Blood and lymphatic system disorders | Pralsetinib 400 mg QD | 285 | 540 | 1,098 |
| other | Anaemia | Blood and lymphatic system disorders | Pralsetinib BID Dosing Schedule | 6 | 9 | 15 |
| other | Anaemia | Blood and lymphatic system disorders | Pralsetinib All Doses | 310 | 590 | 1,168 |
| other | Leukopenia | Blood and lymphatic system disorders | Pralsetinib ≤ 300 mg QD | 4 | 37 | 11 |
| other | Leukopenia | Blood and lymphatic system disorders | Pralsetinib 400 mg QD | 55 | 540 | 226 |
| other | Leukopenia | Blood and lymphatic system disorders | Pralsetinib BID Dosing Schedule | 1 | 9 | 1 |
| other | Leukopenia | Blood and lymphatic system disorders | Pralsetinib All Doses | 61 | 590 | 239 |
| other | Lymphopenia | Blood and lymphatic system disorders | Pralsetinib ≤ 300 mg QD | 7 | 37 | 29 |
| other | Lymphopenia | Blood and lymphatic system disorders | Pralsetinib 400 mg QD | 67 | 540 | 321 |
| other | Lymphopenia | Blood and lymphatic system disorders | Pralsetinib BID Dosing Schedule | 2 | 9 | 8 |
| other | Lymphopenia | Blood and lymphatic system disorders | Pralsetinib All Doses | 77 | 590 | 359 |
| other | Neutropenia | Blood and lymphatic system disorders | Pralsetinib ≤ 300 mg QD | 8 | 37 | 22 |
| other | Neutropenia | Blood and lymphatic system disorders | Pralsetinib 400 mg QD | 124 | 540 | 422 |
| other | Neutropenia | Blood and lymphatic system disorders | Pralsetinib BID Dosing Schedule | 2 | 9 | 6 |
| other | Neutropenia | Blood and lymphatic system disorders | Pralsetinib All Doses | 135 | 590 | 456 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Pralsetinib ≤ 300 mg QD | 3 | 37 | 6 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Pralsetinib 400 mg QD | 44 | 540 | 98 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Pralsetinib BID Dosing Schedule | 1 | 9 | 1 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Pralsetinib All Doses | 48 | 590 | 105 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03037385/events